Is Merck the Next Big Weight-Loss Stock?
And that's why Merck could credibly become the next big weight-loss stock. Before you rush to go buy shares of Merck, ...
FierceBiotech4d
Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug
Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...
FiercePharma2d
Fierce Pharma Asia—Merck's oral GLP-1 play; Astellas' gene therapy deal; Betta's FDA nod
Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a ...
Yahoo Finance3d
MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset
Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical oral ...
Daily2d
Merck, Hansoh Pharma ink pact for oral small molecule GLP-1 receptor agonist
Rahway: Merck, known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, ...
Hosted on MSN2d
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) ...
Why Viking Therapeutics Tumbled by More Than 10% This Week
According to data compiled by S&P Global Market Intelligence, the biotech's share price fell by just over 10% over the period ...